[Illustrations de Art de chevalerie] / [Non identifié] ; Johann Hacobi von Wallhausen, aut. du texte

Comprend : [Frontispice : éléments d'architecture, figures de deux soldats en armure, scène de charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.68 (ou 446) : art équestre. Manière de monter à cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.72 (ou 452) : art équestre. Manière de faire tourner le cheval en une ronde ou dans une figure serpentine.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.78 (ou 460) : art équestre. Manière de faire monter une côte à un cheval, de lui faire sauter un obstacle.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.80 (ou 464) : art équestre. Manière de faire traverser un fleuve à un cheval, de lui faire traverser un pont étroit et de lui faire dominer sa peur du feu. ] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.84 (ou 470) : art équestre. Manière de combattre avec un lance sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.86 (ou 474) : art équestre. Manière de combattre avec un lance ou avec une épéesur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.88 (ou 478) : art équestre. Manière de combattre avec des arquebuses sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.90 (ou 482) : art équestre. Manière de combattre avec des arquebuses ou des épées sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.94 (ou 488) : art équestre. Manière de combattre entre un fantassin et un cavalier.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.96 (ou 492) : art équestre. Manière de combattre entre un fantassin et un cavalier ou entre deux cavalier armés d'épées.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.100 (ou 498) : art équestre. Manière de combattre entre cavaliers.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.102 (ou 502) : art équestre. Manière de combattre entre deux adversaires à pied.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.106 (ou 508) : art équestre. Scène de batailel avec charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Vigentte p.512 : marque d'imprimeur.] [Cote : Res Z Fontanieu 103 (5)]

[Illustrations de L'art du fabricant de velours de coton] / Bernard, grav.; Fossier, dess. ; Jean-Marie Roland de la Platière, aut. du texte

Comprend : [Bandeau folio Aij : allégorie de la Justice. Homme écrivant, singe. Ornements à la Bérin.] [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.1 : de la mécanique à carder le coton. Vues et développements de la machine à carder le coton.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.2 : de la mécanique à carder le coton. Machine à carder le coton.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.3 : de la mécanique à carder le coton. Machine à carder le coton. Fig.4 : petits cadres en fer, implantés sur la charpente de la mécanique, sur lesquels s'appuie et tourne l'axe des cylindres.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.4 : de la mécanique à filer le coton et de la manière de s'en servir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.5 : de la mécanique à filer le coton et de la manière de s'en servir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.6 : fabrication du velours. Fig.1 : moulins à retordre les fils de coton, doublés pour la châine des velours] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.7 : fabrication du velours. Fig.1 : vue perspective du métier monté et en travail.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.8 : fabrication du velours. Armure de piqué pour un carreau quatre points simple ou double, velours velvet-ret, croisé, piqué ou cannelé. Fig.8 : fabrication d'une toile sans lisière.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.9 : fabrication du velours. Le fourneau à brûler, griller ou raser les velours de coton et de la manière de faire cette opération.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.10 avec 3 vignettes : vignette 1, fabrication du velours. Des couleurs en bon teint. Atelier de teinture pour les coulers ordinaires, les garançages etc. Vignette 2 : atelier de teinture pour les cuves de bleu. Vignette 3 : atelier de teinture pour les tones de noir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.11 : fabrication du velours. Des couleurs en bon teint. De la cuve du bleu à chaud. Mécanique à imprimer au cylindre les toiles, croisés, satinettes, velours de coton etc. Mécanique à découper les velours cannelés et le velvet-ret avec l'ouvrier vu en travail. ] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257]

Predicting body weight from body measurements of pre-pubertal Ayshire heifers

Selostus: Hiehojen elopainon määrittäminen mittauksin alkukasvatusvaiheessa

Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.

Huntington's disease is an inherited neurodegenerative disease that causes motor, cognitive and psychiatric impairment, including an early decline in ability to recognize emotional states in others. The pathophysiology underlying the earliest manifestations of the disease is not fully understood; the objective of our study was to clarify this. We used functional magnetic resonance imaging to investigate changes in brain mechanisms of emotion recognition in pre-manifest carriers of the abnormal Huntington's disease gene (subjects with pre-manifest Huntington's disease): 16 subjects with pre-manifest Huntington's disease and 14 control subjects underwent 1.5 tesla magnetic resonance scanning while viewing pictures of facial expressions from the Ekman and Friesen series. Disgust, anger and happiness were chosen as emotions of interest. Disgust is the emotion in which recognition deficits have most commonly been detected in Huntington's disease; anger is the emotion in which impaired recognition was detected in the largest behavioural study of emotion recognition in pre-manifest Huntington's disease to date; and happiness is a positive emotion to contrast with disgust and anger. Ekman facial expressions were also used to quantify emotion recognition accuracy outside the scanner and structural magnetic resonance imaging with voxel-based morphometry was used to assess the relationship between emotion recognition accuracy and regional grey matter volume. Emotion processing in pre-manifest Huntington's disease was associated with reduced neural activity for all three emotions in partially separable functional networks. Furthermore, the Huntington's disease-associated modulation of disgust and happiness processing was negatively correlated with genetic markers of pre-manifest disease progression in distributed, largely extrastriatal networks. The modulated disgust network included insulae, cingulate cortices, pre- and postcentral gyri, precunei, cunei, bilateral putamena, right pallidum, right thalamus, cerebellum, middle frontal, middle occipital, right superior and left inferior temporal gyri, and left superior parietal lobule. The modulated happiness network included postcentral gyri, left caudate, right cingulate cortex, right superior and inferior parietal lobules, and right superior frontal, middle temporal, middle occipital and precentral gyri. These effects were not driven merely by striatal dysfunction. We did not find equivalent associations between brain structure and emotion recognition, and the pre-manifest Huntington's disease cohort did not have a behavioural deficit in out-of-scanner emotion recognition relative to controls. In addition, we found increased neural activity in the pre-manifest subjects in response to all three emotions in frontal regions, predominantly in the middle frontal gyri. Overall, these findings suggest that pathophysiological effects of Huntington's disease may precede the development of overt clinical symptoms and detectable cerebral atrophy.

Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence.

BACKGROUND: We reviewed the current evidence on the benefit and harm of pre-hospital tracheal intubation and mechanical ventilation after traumatic brain injury (TBI). METHODS: We conducted a systematic literature search up to December 2007 without language restriction to identify interventional and observational studies comparing pre-hospital intubation with other airway management (e.g. bag-valve-mask or oxygen administration) in patients with TBI. Information on study design, population, interventions, and outcomes was abstracted by two investigators and cross-checked by two others. Seventeen studies were included with data for 15,335 patients collected from 1985 to 2004. There were 12 retrospective analyses of trauma registries or hospital databases, three cohort studies, one case-control study, and one controlled trial. Using Brain Trauma Foundation classification of evidence, there were 14 class 3 studies, three class 2 studies, and no class 1 study. Six studies were of adults, five of children, and three of both; age groups were unclear in three studies. Maximum follow-up was up to 6 months or hospital discharge. RESULTS: In 13 studies, the unadjusted odds ratios (ORs) for an effect of pre-hospital intubation on in-hospital mortality ranged from 0.17 (favouring control interventions) to 2.43 (favouring pre-hospital intubation); adjusted ORs ranged from 0.24 to 1.42. Estimates for functional outcomes after TBI were equivocal. Three studies indicated higher risk of pneumonia associated with pre-hospital (when compared with in-hospital) intubation. CONCLUSIONS: Overall, the available evidence did not support any benefit from pre-hospital intubation and mechanical ventilation after TBI. Additional arguments need to be taken into account, including medical and procedural aspects.

Biomarker analysis of stored blood products: emphasis on pre-analytical issues.

Millions of blood products are transfused every year; many lives are thus directly concerned by transfusion. The three main labile blood products used in transfusion are erythrocyte concentrates, platelet concentrates and fresh frozen plasma. Each of these products has to be stored according to its particular components. However, during storage, modifications or degradation of those components may occur, and are known as storage lesions. Thus, biomarker discovery of in vivo blood aging as well as in vitro labile blood products storage lesions is of high interest for the transfusion medicine community. Pre-analytical issues are of major importance in analyzing the various blood products during storage conditions as well as according to various protocols that are currently used in blood banks for their preparations. This paper will review key elements that have to be taken into account in the context of proteomic-based biomarker discovery applied to blood banking.

Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.

Background Medication adherence is a complex, dynamic and changing behaviour that is affected by a variety of factors, including the patient's beliefs and life circumstances. Studies have highlighted barriers to medication adherence (e.g., unmanaged side effects or a lack of social support), as well as facilitators of medication adherence (e.g., technical simplicity of treatment and psychological acceptance of the disease). Since August 2004, in Lausanne (Switzerland), physicians have referred patients who are either experiencing or are at risk of experiencing problems with their HIV antiretroviral treatment (ART) to a routine interdisciplinary ART adherence programme. This programme consists of multifactorial intervention including electronic drug monitoring (MEMS(TM)). Objective This study's objective was to identify the barriers and facilitators encountered by HIV patients with suboptimal medication adherence (≤90 % adherence over the study period). Setting The community pharmacy of the Department of Ambulatory Care and Community Medicine in Lausanne (Switzerland). Method The study consisted of a retrospective, qualitative, thematic content analysis of pharmacists' notes that were taken during semi-structured interviews with patients and conducted as part of the ART adherence programme between August 2004 and May 2008. Main outcome measure Barriers and facilitators encountered by HIV patients. Results Barriers to and facilitators of adherence were identified for the 17 included patients. These factors fell into three main categories: (1) cognitive, emotional and motivational; (2) environmental, organisational and social; and (3) treatment and disease. Conclusion The pharmacists' notes revealed that diverse barriers and facilitators were discussed during medication adherence interviews. Indeed, the results showed that the 17 non-adherent patients encountered barriers and benefited from facilitators. Therefore, pharmacists should inquire about all factors, regardless of whether they have a negative or a positive impact on medication adherence, and should consider all dimensions of patient adherence. The simultaneous strengthening of facilitators and better management of barriers may allow healthcare providers to tailor care to a patient's specific needs and support each individual patient in improving his medication-related behaviour.

Samoyedic studies : a state-of-the-art report

Abstract